Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A

Keith W. Pratz; Courtney D. DiNardo; Dominik Selleslag; Junmin Li; Kazuhito Yamamoto; Marina Konopleva; Don Stevens; Hagop Kantarjian; Fabiola Traina; Adriano Venditti; Jiri Mayer; Melissa Montez; Huan Jin; Yinghui Duan; Deanna Brackman; Jiuhong Zha; Jalaja Potluri; Michael Werner; Brian A. Jonas

doi:10.1002/ajh.26692

Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A

Keith W. Pratz, Courtney D. DiNardo, Dominik Selleslag, Junmin Li, Kazuhito Yamamoto, Marina Konopleva, Don Stevens, Hagop Kantarjian, Fabiola Traina, Adriano Venditti, Jiri Mayer, Melissa Montez, Huan Jin, Yinghui Duan, Deanna Brackman, Jiuhong Zha, Jalaja Potluri, Michael Werner, Brian A. Jonas

Leukemia

Research output: Contribution to journal › Letter › peer-review

7 Scopus citations

Original language	English (US)
Pages (from-to)	E416-E419
Journal	American journal of hematology
Volume	97
Issue number	11
DOIs	https://doi.org/10.1002/ajh.26692
State	Published - Nov 2022

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.26692

Cite this

Pratz, K. W., DiNardo, C. D., Selleslag, D., Li, J., Yamamoto, K., Konopleva, M., Stevens, D., Kantarjian, H., Traina, F., Venditti, A., Mayer, J., Montez, M., Jin, H., Duan, Y., Brackman, D., Zha, J., Potluri, J., Werner, M., & Jonas, B. A. (2022). Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A. American journal of hematology, 97(11), E416-E419. https://doi.org/10.1002/ajh.26692

Pratz, KW, DiNardo, CD, Selleslag, D, Li, J, Yamamoto, K, Konopleva, M, Stevens, D, Kantarjian, H, Traina, F, Venditti, A, Mayer, J, Montez, M, Jin, H, Duan, Y, Brackman, D, Zha, J, Potluri, J, Werner, M & Jonas, BA 2022, 'Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A', American journal of hematology, vol. 97, no. 11, pp. E416-E419. https://doi.org/10.1002/ajh.26692

@article{0337fab92b01425faf3d277ab8c187fe,

title = "Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A",

author = "Pratz, {Keith W.} and DiNardo, {Courtney D.} and Dominik Selleslag and Junmin Li and Kazuhito Yamamoto and Marina Konopleva and Don Stevens and Hagop Kantarjian and Fabiola Traina and Adriano Venditti and Jiri Mayer and Melissa Montez and Huan Jin and Yinghui Duan and Deanna Brackman and Jiuhong Zha and Jalaja Potluri and Michael Werner and Jonas, {Brian A.}",

note = "Funding Information: Keith W. Pratz: grant support and advisory board fees from AbbVie, Astellas, Agios, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Jazz Pharmaceuticals, Servier, and Millennium; grant support from Astellas, Boston BioMedical, Celgene, Jazz Pharmaceuticals; Courtney DiNardo: Consultant and on Advisory Boards for AbbVie, Agios, Aprea, Celgene/BMS, ImmuneOnc, Kura, Novartis, Takeda, Notable Labs; research support provided to her institution by AbbVie, Agios, Calithera, Cleave, BMS/Celgene, Daiichi‐Sankyo, ImmuneOnc, Loxo. Dominik Selleslag: Consulting / advisory role for AbbVie, Astellas, Astex‐Otsuka, Celgene/BMS, Daichii Sankyo, Janssen‐Cilag, Novartis, Pfizer, Takeda. Kazuhito Yamamoto: Consulting/advisory role for AbbVie, Astra‐Zeneca, Celgene, Chugai, Daiichi Sankyo, Eisai, HUYA, Meiji Seika Pharma, MSD, Mundipharma, Ono, Otsuka, Stemline Therapeutics and Takeda; lecture fees from AbbVie, Bristol‐Myers Squibb, Celgene, Chugai, Eisai, IQIVA/HUYA, Janssen, Kyowa Kirin, Meiji Seika Pharma, MSD, Mundipharma, Nippon Shinyaku, Novartis, Ono, Otsuka, Pfizer, Sanofi, Sumitomo Dainippon and Takeda; research funding to his institution from AbbVie, Astra‐Zeneca, Bayer, Celgene, Chugai, Eisai, Gilead Sciences, IQIVA/Incyte, MSD, Mundipharma, Nippon Shinyaku, Novartis, Ono, Otsuka, Solasia Pharma, SymBio, Takeda, Yakult and Zenyaku. Adriano Venditti: Consultant and on Advisory Boards for AbbVie, Pfizer, Amgen, Novartis, Astellas, Daiichi‐Sankyo, Gilead, Jazz‐Pharmaceuticals; research support provided to his institution by Sandoz, Jazz‐Pharmaceuticals. Jiri Mayer: Research grants from AbbVie. Melissa Montez and Huan Jin: Employees of Genentech and may hold Roche stock or options. Yinghui Duan, Deanna Brackman, Jiuhong Zha, Jalaja Potluri, Michael Werner: Employees of AbbVie and may hold stock or options. Brian Jonas: Consulting/advisory role for: AbbVie, BMS, Genentech, Gilead, GlycoMimetics, Jazz, Pfizer, Servier, Takeda, Tolero, and Treadwell; protocol steering committee for GlycoMimetics; data monitoring committee for Gilead; travel reimbursement from AbbVie; research funding to his institution from 47, AbbVie, Accelerated Medical Diagnostics, Amgen, AROG, BMS, Celgene, Daiichi Sankyo, F. Hoffmann‐La Roche, Forma, Genentech/Roche, Gilead, GlycoMimetics, Hanmi, Immune‐Onc, Incyte, Jazz, Loxo, LP Therapeutics, Pfizer, Pharmacyclics, Sigma Tau, and Treadwell. The other authors have no conflicts of interest to disclose. Funding Information: The authors wish to thank the patients and their families, the study coordinators, and support staff. The authors would also like to acknowledge all investigators of the NCT02993523 study. Medical writing support was provided by Hayley Ellis, PhD, of Fishawack Communications Ltd, funded by AbbVie. Venetoclax is being developed in a collaboration between AbbVie and Genentech. AbbVie and Genentech funded this study (NCT02993523) and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this manuscript. No honoraria or payments were made for authorship.",

year = "2022",

month = nov,

doi = "10.1002/ajh.26692",

language = "English (US)",

volume = "97",

pages = "E416--E419",

journal = "American journal of hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "11",

}

TY - JOUR

T1 - Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A

AU - Pratz, Keith W.

AU - DiNardo, Courtney D.

AU - Selleslag, Dominik

AU - Li, Junmin

AU - Yamamoto, Kazuhito

AU - Konopleva, Marina

AU - Stevens, Don

AU - Kantarjian, Hagop

AU - Traina, Fabiola

AU - Venditti, Adriano

AU - Mayer, Jiri

AU - Montez, Melissa

AU - Jin, Huan

AU - Duan, Yinghui

AU - Brackman, Deanna

AU - Zha, Jiuhong

AU - Potluri, Jalaja

AU - Werner, Michael

AU - Jonas, Brian A.

N1 - Funding Information: Keith W. Pratz: grant support and advisory board fees from AbbVie, Astellas, Agios, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Jazz Pharmaceuticals, Servier, and Millennium; grant support from Astellas, Boston BioMedical, Celgene, Jazz Pharmaceuticals; Courtney DiNardo: Consultant and on Advisory Boards for AbbVie, Agios, Aprea, Celgene/BMS, ImmuneOnc, Kura, Novartis, Takeda, Notable Labs; research support provided to her institution by AbbVie, Agios, Calithera, Cleave, BMS/Celgene, Daiichi‐Sankyo, ImmuneOnc, Loxo. Dominik Selleslag: Consulting / advisory role for AbbVie, Astellas, Astex‐Otsuka, Celgene/BMS, Daichii Sankyo, Janssen‐Cilag, Novartis, Pfizer, Takeda. Kazuhito Yamamoto: Consulting/advisory role for AbbVie, Astra‐Zeneca, Celgene, Chugai, Daiichi Sankyo, Eisai, HUYA, Meiji Seika Pharma, MSD, Mundipharma, Ono, Otsuka, Stemline Therapeutics and Takeda; lecture fees from AbbVie, Bristol‐Myers Squibb, Celgene, Chugai, Eisai, IQIVA/HUYA, Janssen, Kyowa Kirin, Meiji Seika Pharma, MSD, Mundipharma, Nippon Shinyaku, Novartis, Ono, Otsuka, Pfizer, Sanofi, Sumitomo Dainippon and Takeda; research funding to his institution from AbbVie, Astra‐Zeneca, Bayer, Celgene, Chugai, Eisai, Gilead Sciences, IQIVA/Incyte, MSD, Mundipharma, Nippon Shinyaku, Novartis, Ono, Otsuka, Solasia Pharma, SymBio, Takeda, Yakult and Zenyaku. Adriano Venditti: Consultant and on Advisory Boards for AbbVie, Pfizer, Amgen, Novartis, Astellas, Daiichi‐Sankyo, Gilead, Jazz‐Pharmaceuticals; research support provided to his institution by Sandoz, Jazz‐Pharmaceuticals. Jiri Mayer: Research grants from AbbVie. Melissa Montez and Huan Jin: Employees of Genentech and may hold Roche stock or options. Yinghui Duan, Deanna Brackman, Jiuhong Zha, Jalaja Potluri, Michael Werner: Employees of AbbVie and may hold stock or options. Brian Jonas: Consulting/advisory role for: AbbVie, BMS, Genentech, Gilead, GlycoMimetics, Jazz, Pfizer, Servier, Takeda, Tolero, and Treadwell; protocol steering committee for GlycoMimetics; data monitoring committee for Gilead; travel reimbursement from AbbVie; research funding to his institution from 47, AbbVie, Accelerated Medical Diagnostics, Amgen, AROG, BMS, Celgene, Daiichi Sankyo, F. Hoffmann‐La Roche, Forma, Genentech/Roche, Gilead, GlycoMimetics, Hanmi, Immune‐Onc, Incyte, Jazz, Loxo, LP Therapeutics, Pfizer, Pharmacyclics, Sigma Tau, and Treadwell. The other authors have no conflicts of interest to disclose. Funding Information: The authors wish to thank the patients and their families, the study coordinators, and support staff. The authors would also like to acknowledge all investigators of the NCT02993523 study. Medical writing support was provided by Hayley Ellis, PhD, of Fishawack Communications Ltd, funded by AbbVie. Venetoclax is being developed in a collaboration between AbbVie and Genentech. AbbVie and Genentech funded this study (NCT02993523) and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this manuscript. No honoraria or payments were made for authorship.

PY - 2022/11

Y1 - 2022/11

UR - http://www.scopus.com/inward/record.url?scp=85137974335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85137974335&partnerID=8YFLogxK

U2 - 10.1002/ajh.26692

DO - 10.1002/ajh.26692

M3 - Letter

C2 - 36054316

AN - SCOPUS:85137974335

SN - 0361-8609

VL - 97

SP - E416-E419

JO - American journal of hematology

JF - American journal of hematology

IS - 11

ER -

Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this